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Abstract
Background: Care management programmes are an effective approach to care for high risk patients with complex
care needs resulting from multiple co-occurring medical and non-medical conditions. These patients are likely to
be hospitalized for a potentially “avoidable” cause. Nurse-led care management programmes for high risk elderly
patients showed promising results. Care management programmes based on health care assistants (HCAs)
targeting adult patients with a high risk of hospitalisation may be an innovative approach to deliver cost-efficient
intensified care to patients most in need.
Methods/Design: PraCMan is a cluster randomized controlled trial with primary care practices as unit of
randomisation. The study evaluates a complex primary care practice-based care management of patients at high
risk for future hospitalizations. Eligible patients either suffer from type 2 diabetes mellitus, chronic obstructive
pulmonary disease, chronic heart failure or any combination. Patients with a high likelihood of hospitalization
within the following 12 months (based on insurance data) will be included in the trial.
During 12 months of intervention patients of the care management group receive comprehensive assessment of
medical and non-medical needs and resources as well as regular structured monitoring of symptoms. Assessment
and monitoring will be performed by trained HCAs from the participating practices. Additionally, patients will
receive written information, symptom diaries, action plans and a medication plan to improve self-management
capabilities. This intervention is addition to usual care.
Patients from the control group receive usual care.
Primary outcome is the number of all-cause hospitalizations at 12 months follow-up, assessed by insurance claims
data. Secondary outcomes are health-related quality of life (SF12, EQ5D), quality of chronic illness care (PACIC),
health care utilisation and costs, medication adherence (MARS), depression status and severity (PHQ-9), self-
management capabilities and clinical parameters. Data collection will be performed at baseline, 12 and 24 months
(12 months post-intervention).
Discussion: Practice-based care management for high risk individuals involving trained HCAs appears to be a
promising approach to face the needs of an aging population with increasing care demands.
Trial registration: Current Controlled Trials ISRCTN56104508
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Healthcare systems are challenged by an increasing
number of patients with multiple chronic conditions [1].
Individuals with multiple chronic conditions are more
likely to be at risk for functional impairment [2] and
adverse drug events [3]. Self management capabilities
decline with an increasing number of co-occurring med-
ical conditions [4]. In addition, medical care for patients
with multiple chronic conditions is often fragmented by
poor coordination between different healthcare provi-
ders [5]. These patients are more likely to be hospita-
lised for a potentially ‘avoidable’ cause (e.g., unmanaged
exacerbation, intermittent infection or falls, imperfect
transitional care), leading to suboptimal health outcomes
[6] and substantial healthcare costs [7].
Particularly primary care faces a challenge to care for
patients with multiple chronic conditions on the back-
ground of limited human and restricted financial
resources [8,9]. Different suggestions are available to
take up the challenge by re-organising the delivery of
chronic illness care [10,11]. Based on these concepts,
care management interventions have been developed
and evaluated focusing on patients with multiple chronic
conditions. These interventions share four core elements
[12]: (a) comprehensive assessment of patients’ medical
and non-medical needs and resources, (b) implementa-
tion and monitoring of individualised, evidence-based
care plans, (c) coordination of services between provi-
ders of medical and social care, and (d) enhancement of
self-management capabilities among patients and care-
givers. Despite positive effects on quality of care and
patients’ quality of life, the effect on healthcare utilisa-
tion and costs remains heterogeneous [9]. Care manage-
ment interventions have shown to be effective and
efficient if they focus on patients with high risk of
healthcare utilization [9,13].
It is crucial to identify the patients most likely to ben-
efit from care management programs (case finding).
Based on insurance claims data, so called predictive
models can be used to identify patients at high risk for
future health care utilization [14]. However, not all high
risk patients are able and willing to participate in care
management programs. Thus, case finding by predictive
modelling should be complemented by the treating phy-
sician who can identify high risk patients most likely to
participate in and benefit from care management [15].
In Germany, chronic heart failure (CHF), chronic
obstructive pulmonary disease (COPD), and type 2 dia-
betes mellitus (DM) were among the 20 most frequent
causes for hospital admission in 2009 [16]. All three
conditions are ‘ambulatory care sensitive conditions’
(ACSC), meaning that primary care plays an important
role in preventing hospital admissions for these
conditions [17]. These hospitalisations may be avoidable
by coordinated and structured chronic care. Based on
exploratory studies, we developed a primary care prac-
tice-based care management intervention for patients
suffering from any of these index conditions with a high
likelihood of hospitalization as predicted by a statistical
model [18]. Nearly all of these patients suffer from sig-
nificant co-morbidities [19,20]. The care management
intervention is designed to account for the complex care
needs resulting from these co-morbidities.
Chronic care in Germany is mainly delivered by small
primary care practices: The practice team usually con-
sists of one or two physicians (general practitioner or
general internist) and a small number of healthcare
assistants (HCAs), who perform few clinical tasks. HCAs
are trained in a three-year part-time curriculum in prac-
tice (3920 hours) and vocational school (840 hours).
Despite some recent attempts to involve HCAs in
chronic care [21], their work is mostly focused on cleri-
cal work (including reception) and routine tasks like
blood sampling or electrocardiogram recording. How-
ever, recent trials on primary care-based disease-specific
case management interventions involving trained HCAs
showed promising results in patients with osteoarthritis,
[22], depression [23] and systolic heart failure [24].
Moreover, practice teams experienced the expanded role
of HCAs as valuable resource to enhance the provision
of chronic care [25-27].
Novel aspects of PraCMan
Whereas international research on care management has
mainly focused on nurse-led programmes, evidence on
the potential role and effects of HCAs in chronic care is
scarce. As cost-efficiency of intensified care programs
appears to be essential for further implementation,
HCA-based programmes may offer an opportunity to
deliver intensified care with lower staff costs.
The limited medical education of HCAs could be a
potential problem in the care for high-risk patients with
multiple chronic conditions and needs to be addressed
when designing HCA-based programs. Therefore, PraC-
Man focuses on three index conditions (DM, CHF,
COPD) and distinct comorbidity patterns which we
could explore to be common in a population of patients
at high risk for future hospitalization [28]. Furthermore,
structured written protocols for assessment and moni-
toring are feasible tools for HCA-based care manage-
ment programs [29,30]. We designed a modular concept
of structured monitoring lists that can be applied either
by phone or in the practice. This concept accounts for
index conditions as well as for frequent comorbidities.
As case finding has shown to be crucial for the
success of intensified care programs, we selected a
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predicts future hospitalization instead of costs. A signifi-
cant proportion of these hospitalizations account for
“actionable costs” as they appear to be potentially avoid-
able. This predictive model proved to be useful to iden-
tify patients in need for intensified care [15].
Primary care practice-based care management for
patients with either DM, COPD or CHF and a high pre-
dicted risk for future hospitalization involving HCAs is a
promising approach for effective and cost-efficient
intensified care for the patients most in need. This
paper describes aim and methods of the PraCMan trial.
Methods/Design
Primary objective
The primary objective of this study is to determine
whether a primary care practice-based care management
intervention will reduce the number of all-cause hospi-
talizations as compared to standard care. The interven-
tion focuses on patients at high risk for future
hospitalizations suffering from DM, COPD, CHF or any
combination of these index conditions. The intervention
is additional to usual care.
Secondary objectives
We will explore effects on re-admissions, disease-speci-
fic admissions, hospital days, mortality, health-related
quality of life, self-management capabilities, medication
adherence, physical outcome parameters (e.g. NYHA,
number of exacerbations, depressive symptoms),
patients’ satisfaction with medicalc a r e ,h e a l t hs e r v i c e
utilization and costs. Besides, we will explore the effects
of the intervention on work satisfaction of primary care
p h y s i c i a n s( P C P s )a n dH C A sa sw e l la sp r a c t i c e
organization.
Study design
The study is designed as a prospective two-armed open
cluster randomized controlled trial. Randomization at
the level of primary care practice was chosen to prevent
contamination between intervention and control
patients. Blinding of either patients or practice teams
was not possible due to the character of the interven-
tion. However, observers will be blinded during data col-
lection regarding primary and secondary endpoints.
Patients were randomized in clusters of 15-20 patients
per practice (see Figure 1). Each patient was assigned to
a care management team (CM team) consisting of one
PCP and one HCA. All primary and secondary end-
points will be measured at either practice or patient
level at baseline (T0), at 12 months (T1) and 24 months
(T2) after randomization.
Sample size calculation
Sample size was calculated by using the primary end-
point, i.e. the number of all-cause hospitalizations per
patient in the 12 months intervention period. Based on
data from our pilot study, we estimated a mean number
of 0.7 all-cause hospitalizations per patient per year with
a standard deviation of 1 [18]. Based on these estimates,
a total of 1602 patients (801 per arm) would be required
to detect a between-group difference of 0.14 (20%
Figure 1 Design of the PraCMan trial. This figure shows design and timeframe of the PraCMan trial.
Freund et al. Trials 2011, 12:163
http://www.trialsjournal.com/content/12/1/163
Page 3 of 9absolute reduction) with a power of 80% and by using a
two-sample t-test at a 5% significance level (two-sided).
An intracluster correlation ( I C C )o f0 . 0 1a tp r a c t i c e
level could be estimated on the basis of data from a
comparable intervention study [24]. Assuming an ICC
of 0.01 and an average cluster size of 17, we estimated a
design effect of D = 1 + (17 - 1) × 0.01 = 1.16. Taking
this design effect into account, a total of 110 practices
and 1870 patients (55 practices and 935 patients per
arm) will be required. Recent intervention studies
reported drop-out rates of 6% [31] and 10% [24], respec-
tively. Therefore, assuming a drop out rate of 15%, we
aimed to include 2,210 patients and 130 practices.
Recruitment of practice sites and patients
PCPs were eligible for the study if they were participat-
ing in the primary care-centred care contract of the
General Regional Health Fund (AOK). Participation in
the primary care (PC)-centred care contract is voluntary
for physicians and patients. Care within this contract
implies a gate keeping role of the PCP, PCP training
and feedback regarding evidence based pharmacotherapy
and patient benefits such as reduced waiting times in
the practice and late afternoon consultation hours.
We invited eligible PCPs in the Federal State of
Baden-Württemberg (Germany) by a formal letter to
participate in the study. 132 PCPs from 115 practices
gave their written consent and were randomized into
the study groups. 234 PCPs gave information before
randomization that they decline to participate due to
lack of time (n = 129), practice organization (n = 16),
unattractive reimbursement (n = 7), no interest (n = 2),
concerns about funding source (n = 1), health status of
PCP (n = 4) and plans about giving-up practice in near
future (n = 7). 63 PCPs did not further specify their rea-
son for declined participation, whereas 5 PCPs were not
able to recruit study patients and withdrew participation
before randomization.
From the study coordinating centre PCPs received a
list of potentially eligible patients based on inclusion
and exclusion criteria (see below). After validation of
their eligibility patients were recruited by participating
PCPs who were blinded to their allocation to the study
groups. Patients not willing to participate were asked to
give a reason for their decision (on a voluntary basis).
PCPs were asked to document patients screened, asked
and not included as well as the reason for inclusion and
exclusion.
Randomization
Practices were randomly allocated to care management
or usual care in the ratio of 1:1. We performed block
randomisation with variable block lengths to ensure
study groups of approximately equal size. As population
density has shown to have significant impact on hospita-
lizations [32], cluster randomization was stratified
according to population density of the regions of partici-
pating practice sites based on a map provided by the
Federal Agency of Regional Development Planning [33].
We used computer generated randomization lists (SAS
Version 9.2). Separate randomisation lists were prepared
for urban and rural practices. Central randomisation
was performed by a research assistant who was not
involved in the project. PCPs allocation to either inter-
vention or control group remained concealed until
patient recruitment in the practice was fully completed.
After this, PCPs were informed about their allocation
with an official letter from the study coordinating
centre.
Inclusion/Exclusion criteria
Practice inclusion and exclusion criteria
Eligible primary care practices had to fulfil the following
criteria: Participation in the PC-centred care contract of
the AOK-Baden-Württemberg, at least one PCP (e.g.
general practitioner or general internist) who was willing
to participate in the study, at least one participating
HCA, and the ability to perform on-site spirometry and
home visits.
Practices which quit participation in the PC-centred
care contract of the AOK-Baden-Württemberg during
the study will be excluded. Participation in similar clini-
cal trials (e.g. telemonitoring studies) is exempted for
participating practices.
Patient inclusion and exclusion criteria
To be eligible for the study, patients had to suffer from
at least one of the following index conditions: type 2
diabetes mellitus under medical treatment and/or
chronic obstructive pulmonary disease under medical
treatment and/or chronic heart failure with confirmed
diagnosis by a cardiologist. Further inclusion criteria
were: High risk for future hospitalization (i.e. predicted
likelihood of hospitalization within the upper quartile of
the total patient population) and age ≥ 18 years.
The likelihood of at least one hospitalization within
the next 12 months (LOH) was calculated on the basis
of pseudonymised insurance claims data of all AOK
beneficiaries from the participating practices. The soft-
ware package Case Smart Suite Germany 0.7 (Verisk
Health, Munich, Germany) was used to compute LOH.
The software calculates LOH on the basis of all ICD10-
GM (German modification) inpatient and outpatient
diagnosis codes, prior costs and hospital admissions as
well as demographic data. All input variables were
obtained for a pre-prediction interval of 18 months [15].
Patients with the following criteria were excluded:
Active cancer disease (defined as cancer diagnosis under
current treatment with radiotherapy or chemotherapy),
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nursing home, participation in a concurrent clinical trial
(involving telemonitoring studies), severe physical and
mental disorders or other problems that hinder active
participation in the intervention (e.g. Non-German
speaking patients).
Data collection
After obtaining written informed consent, patients were
registered in the study coordinating centre of the
Department of General Practice and Health Services
Research Heidelberg (Germany) which is responsible for
administration, coordination, data management and
monitoring (includes database-set up and validation,
data entry, coding, and query management).
Patients will be asked to fill in a pseudonymised
paper-based questionnaire. PCPs will document addi-
tional data from patients’ chart and assess the clinical
status of the patient (e.g. dyspnoea, blood pressure).
Patient questionnaire and chart review will be per-
formed at baseline, 12-, and 24- month follow-up. In
addition to these data sources, pseudonymised insurance
claims data of participating patients will be obtained
from the AOK including data on health service utilisa-
tion, medication, diagnosis and costs. All data from
patient questionnaires, case report forms and insurance
claims will be compiled.
Outcome measures
Primary outcome
The number of all-cause hospitalizations per patient
during 12 months of follow up will be determined on
the basis of insurance claims data.
Secondary outcomes
Additional information regarding hospital admissions
will be obtained from a chart review (planned/un-
planned admission) and case report forms. Health-
related quality of life will be assessed using the Short
Form 12 Health Questionnaire (SF-12) and the EuroQol
instrument EQ-5D (see table 1). Other secondary out-
come parameters are: Patient Assessment of Chronic Ill-
ness Care (PACIC), Medication Adherence (MARS),
depression (PHQ-9), self-management capabilities
(European Heart Failure Selfcare Behaviour Scale, self-
developed scales for DM- and COPD-related self
management), physical activity (RAPA), activities of
daily living (ADL/IADL), mortality, healthcare utilization
(emergency department visits, practice visits, skilled nur-
sing home days) and total healthcare costs. Additionally,
clinical parameters will be assessed for all patients
(blood pressure), DM-patients (HbA1c, number of
(severe) hypoglycaemias, fasting glucose), COPD-
patients (MRC dyspnoea sale, forced expiratory volume,
number of exacerbations) and CHF-patients (NYHA,
number of exacerbations). Qualitative (focus groups
with PCPs, HCAs and patients) as well as quantitative
(CM documents) process evaluation is planned in order
to investigate how the PraCMan intervention is imple-
mented into practice.
Statistical analysis
Data will be analysed in accordance with the CONSORT
statement and its extension for cluster randomised trials
[34]. The primary analysis will be performed adhering to
the intention-to-treat principle. An additional sensitivity
analysis will be conducted on a per-protocol analysis set.
Descriptive statistics will be used to summarise charac-
teristics of both practices and patients. A multilevel
modelling approach [35] will be applied to evaluate dif-
ferences between the intervention group and the control
group on the primary and all secondary outcomes. This
approach will be used to account for the hierarchical
structure of the data (i.e. patients nested within
practices). Evaluations will include analyses of subgroups
based on morbidity, health care utilization and predicted
risk of future hospitalization. The effect of the interven-
tion on the primary outcome will be tested at the
two-sided significance level of 5%. The result will be
presented as the difference between group means with
the corresponding 95% confidence interval after adjust-
ment for baseline characteristics. Only the result of this
primary efficacy analysis will be interpreted in a confir-
matory manner. Interim analyses are not planned.
Statistical analyses will be carried out with SAS Version
9.2 (SAS Institute, Cary, NC, USA).
Intervention
PraCMan is a complex care management intervention
[36]. Based on the results of a series of exploratory stu-
dies [18] a multifaceted intervention was developed to
reduce (avoidable) hospitalizations of high risk patients.
The intervention consists of three elements:
Assessment
At the beginning, all patients receive an assessment of
medical and non-medical needs and resources using a
structured protocol by a practice-based HCA. Contents
are: Vaccination status (Influenza, Streptococcus pneu-
monia), allergies, nutritional problems, depression, falls,
medication adherence, medication ("brown bag review”),
pain, physical activity, smoking status, hearing/seeing
problems, constipation, and financial/social situation. In
accordance with patient-centred care patients will be
asked to prioritise the three most important problems -
no matter whether medical or non-medical [37]. The
assessment can be performed at a home visit if patients
are immobile. Patients with a high risk of falls (deter-
mined by the assessment) will receive a preventive home
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tripping hazards.
Planning
At a first step, PCPs and HCAs will discuss the results
of the assessment in order to identify needs that can be
targeted by care management. These targets will be
refined in collaboration with patients and caregivers, if
applicable: Patients will be motivated to set long-term
goals for CM. Patients and CM teams will then jointly
define concrete steps (short-term goals) needed to
achieve the long term goals. Self-efficacy to achieve
these short term goals will be assessed using a 10-step
Likert Scale ("How confident are you that you will take
this step during the next XY weeks?”). A 0 displays
“absolute no confidence”,1 0d i s p l a y s“absolute confi-
dence”. If patients rate their self-efficacy lower than 7,
concrete steps will be further discussed in order to set a
more realistic short term goal. As part of care planning,
all patients will receive a patient folder containing dis-
ease specific information leaflets, symptom diaries,
action plans for self-managing acute exacerbations, a list
of diagnosis and allergies, a current medication list,
medical reports, lab results, and contact data of the
PCP. Additionally, long and short term goals will be
documented in the patient folder. The patient is encour-
aged to take the folder to each medical encounter. The
first page of the folder contains a red box for hospital
doctors prompting them to call the PCP at least 24
hours prior to discharge. Patients will be trained in the
Table 1 Outcome parameter and instruments of the PraCMan trial
Outcome parameter Instrument Data
source
Primary outcome
All-cause hospitalizations Data on admissions IC
Secondary outcomes
Sociodemographic data Single items from German standard questionnaire [44] PQ
Mortality Patient chart CRF/IC
Quality of Life EuroQol (EQ-5D) [45] PQ
Short Form 12 Health Questionnaire (SF 12) [46] PQ
Quality of Care Patient Assessment of Chronic Illness Care (PACIC) [47] PQ
Depression Patient Health Questionnaire (PHQ9) [48] PQ
Adherence Medication Adherence Reporting Scale (MARS) [49] PQ
Physical Activity The Rapid Assessment of Physical Activity (RAPA) [50] PQ
Smoking status Self developed items CRF
Self-management CHF European Selfcare Behaviour Scale (EHFScB) [51] PQ
Self-management COPD/DM Self developed instrument PQ
Medication regimen Pharmacy data IC
Healthcare costs Data from hospital care, ambulatory care, nursing facilities, pharmacies, rehabilitation IC
Activities of daily living ADL [52]
IADL [53]
CRF
Comorbidity Cumulative Illness Rating Scale (CIRS) [54] CRF
Home visits/Practice visits Self developed items CRF
CHF decompensation (CHF patients) Self developed items CRF
COPD exacerbation (COPD patients) Self developed items CRF
Hypoglycaemia (DM patients) Self developed items CRF
Body mass index Weight, Height CRF
Blood pressure (all patients) Standardized Measurement in the practice CRF
Fasting glucose Patient chart CRF
Hemoglobin-A1c Patient chart CRF
Dyspnoea (CHF and COPD patients) Current NYHA-classification (CHF patients) or current MRC Dyspnoe Score (COPD patients)
[55]
CRF
Forced expiratory volume (COPD
patients)
Standardized Measurement in the practice CRF
PQ: Patient questionnaire, CRF: Case Report Form, IC: Insurance claims data.
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with their HCA.
Monitoring
Practice-based HCAs will deliver a regular telephone
monitoring using the PraCMan monitoring list. Content
and frequency of the monitoring will be determined by
the PCP. A core module of monitoring items is fixed for
all patients. Modules on DM, COPD, CHF, and
depression could be selected for individual conditions.
Frequency of monitoring is stratified by patients’ risk for
clinical deterioration: level 1 indicating 6-weekly
contacts (low risk of acute deterioration of symptoms),
level 2 indicating 3-weekly contacts (moderate risk of
acute deterioration of symptoms) and level 3 triggering
weekly contacts (high risk acute deterioration of symp-
toms, e.g. first days after discharge from an unplanned
hospitalization).
The PraCMan monitoring list has been developed
based on experiences in prior studies of our group and
will be published elsewhere [29,30]. Item responses are
colour-coded green, yellow, or red according to the
urgency of the symptoms and signs presented by the
patient which will guide the HCA-PCP interaction.
Red-coloured answers require immediate contact to the
PCP, orange-coloured answers require the patient to be
seen within 24 hours and yellow-coloured responses are
reported to the PCP within 3 days.
Training of Case Management teams
Prior to the beginning of the intervention, all CM teams
will be trained according to a team-based training curri-
culum. The curriculum was developed based on litera-
ture review, experiences from prior studies [23,24] and
exploratory studies [18] and will be published elsewhere.
Completion of a 36 hour training course (20 hours self-
study, 16 hours interactive workshop) is mandatory for
participating HCAs. PCPs will be invited to take part in
an 8 hour workshop. PCPs and HCAs will be trained
jointly in communication techniques and goal-setting in
order to enhance communication within the CM-team.
Control
Practice teams in the control group will continue to
provide standard care in the context of the PC-centred
care contract [38]. This involves gate keeping for
enrolled patients as well as regular training in evidence-
based guidelines through structured pharmacotherapy
feedback in peer review groups [39]. As population-
based disease management programs (DMPs) for DM,
COPD and CHF (based on coronary heart disease) are
part of routine care in Germany, patients may volunta-
rily participate in these disease specific care programs.
German DMPs consist of regular follow up visits up to
every three months. They include clinical examination,
laboratory tests (e.g. HbA1c tests) and patient education
[40]. However, essential elements of care management
interventions like individualized assessment, care plan-
ning and frequent (symptom) monitoring are not routi-
nely part of DMPs [41].
Ethics and legal aspects
The study is being conducted in accordance with medi-
cal professional codex and the Helsinki Declaration as
well as the ICH Guideline for Good Clinical Practice
(GCP). The study is also in accordance with German
Federal Data Security Law (BDSG). All professionals
participating in the study oblige to adhere to the above-
mentioned declarations and laws. The study protocol
was approved by the ethics committee of the University
Hospital Heidelberg (S-232/2010) and by the ethics
committee of the Federal Medical Association Baden-
Wuerttemberg (B-F-2010-043) prior to the start of the
study. The study is registered at http://www.controlled-
trials.com (ISRCTN56104508).
Timeframe of the study
Practice recruitment was performed between November
2009 and August 2010 (see Figure 1). Recruitment of
eligible patients and baseline data collection started in
September 2010. After cluster randomization, all CM-
teams in intervention practices were trained prior to the
beginning of the intervention in November and Decem-
ber 2010. Data collection for intermediate and final
assessment of outcome parameters is scheduled for
December 2011 (end of intervention) and December
2012 (1 year post intervention).
Discussion
Primary care practice-based care management for
chronically ill patients at high risk for hospitalisation
involving trained HCAs may improve patients’ needs
and outcomes. HCAs have increasingly been recognised
as an underexploited resource in chronic care [42]. In
Germany, additional qualification programmes for
HCAs have recently been installed [43]. The PraCMan
training curriculum for HCAs is designed to comple-
ment these programs and could therefore be implemen-
ted into routine care. Provided that our intervention
proves to be effective, this care program could be disse-
minated throughout PC-centred care contracts nation-
wide. We designed PraCMan to reduce health care
costs by reducing the number of avoidable hospitaliza-
tions. Either budget neutrality or net savings would
provide a rationale for health funds to offer this care
management program, especially if it also improves
quality of care, quality of life, and self management
capabilities of patients.
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